Nothing Special   »   [go: up one dir, main page]

Kam et al., 1978 - Google Patents

Effects of tolerogenic conjugates in a canine model for reaginic hypersensitivity: I. Suppression of hapten-specific IgE antibody response

Kam et al., 1978

View PDF
Document ID
13471894341191196413
Author
Kam S
Kepron W
Sehon A
Publication year
Publication venue
Journal of Allergy and Clinical Immunology

External Links

Snippet

Intraperitoneal administration to dogs of conjugates consisting of the 2, 4-dinitrophenyl (DNP) groups coupled to nonimmunogenic macromolecules such as the copolymer of d- glutamic acid and d-lysine (DNP 16-DGL) prior to sensitization with DNP 2-ovalbumin led to …
Continue reading at www.jacionline.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • A61K47/4833—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/06—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Ishizaka Cellular events in the IgE antibody response
Moreau et al. The absence of gut flora, the doses of antigen ingested and aging affect the long-term peripheral tolerance induced by ovalbumin feeding in mice
Lee et al. Suppression of reaginic antibodies with modified allergens: II. Abrogation of reaginic antibodies with allergens conjugated to polyethylene glycol
Howard et al. Lack of neonatal susceptibility to induction of tolerance by polysaccharide antigens
Holt et al. Tolerance induction via antigen inhalation: isotype specificity, stability, and involvement of suppressor T cells
Cox et al. Oral induction of the secretory antibody response by soluble and particulate antigens
Usui et al. IgE-Selective and Antigen-Specific Unresponsiveness in Mice: I. Induction of the Unresponsiveness by Administration of Ovalbumin-Pullulan Conjugate
NO144056B (en) DEVICE FOR ARTIFICIAL WATERING OF FLOWER BEDS, GARDENS ETC.
Thorbecke et al. Tolerance in adult rabbits by repeated non-immunogenic doses of bovine serum albumin
Chiorazzi et al. Induction if immunological tolerance to the major antigenic determinant of penicillin: a therapeutic approach to penicillin allergy.
Klaus et al. B cell tolerance induced by polymeric antigens. I. Comparison of thedose and epitope density requirement for inactivation of primed and unprimed B cells in vivo
Thomas et al. Reaginic antibody produced in mice with contact sensitivity.
David Prevention of homocytotropic antibody formation and anaphylactic sensitization by prefeeding antigen
Kam et al. Effects of tolerogenic conjugates in a canine model for reaginic hypersensitivity: I. Suppression of hapten-specific IgE antibody response
Lee et al. Suppression of Reaginic Antibody Formation: IV. Suppression of Reaginic Antibodies to Penicillin in the Mouse
Lee et al. Suppression of Reaginic Antibody Formation: III. Relationship Between Immunogenicity and Tolerogenicity of Hapten-Carrier Conjugates
Hostoffer et al. Kabuki Make-up Syndrome Associated with an Acquired Hypogammaglobulinemia and Anti IgA Antibodies
Klipstein et al. Arousal of mucosal secretory immunoglobulin A antitoxin in rats immunized with Escherichia coli heat-labile enterotoxin
Sehon et al. Suppression of immunoglobulin E antibodies with modified allergens
Segawa et al. Suppression of IgE antibody response by the fatty acid-modified antigen
Thompson et al. Tolerogenic activity of polymerized type II collagen in preventing collagen-induced arthritis in rats
Goldschmidt et al. The immune response to homologous lens crystallin. I. Antibody production after lens injury.
Zembala et al. The induction of delayed hypersensitivity by macrophage-associated antigen: The role of macrophage cytophilic antibody
Filion et al. Suppression of the IgE antibody response to ovalbumin in mice with a conjugate of ovalbumin and isologous γ-globulins
Peri et al. Circulating antitoxin in rabbits after ingestion of diphtheria toxoid